希突起膠腫(Oligodendroglioma)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Oligodendroglioma Overview 8
Therapeutics Development 9
Pipeline Products for Oligodendroglioma – Overview 9
Pipeline Products for Oligodendroglioma – Comparative Analysis 10
Oligodendroglioma – Therapeutics under Development by Companies 11
Oligodendroglioma – Therapeutics under Investigation by Universities/Institutes 12
Oligodendroglioma – Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Oligodendroglioma – Products under Development by Companies 15
Oligodendroglioma – Products under Investigation by Universities/Institutes 16
Oligodendroglioma – Companies Involved in Therapeutics Development 17
Cavion LLC 17
Celgene Corporation 18
Celldex Therapeutics, Inc. 19
e-Therapeutics plc 20
Eli Lilly and Company 21
F. Hoffmann-La Roche Ltd. 22
Millennium Pharmaceuticals, Inc. 23
Novartis AG 24
Orbus Therapeutics, Inc. 25
Sanofi 26
Tocagen Inc. 27
Oligodendroglioma – Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
alisertib – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
bevacizumab – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
CC-122 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Dendritic Cell Therapy for Gliomas – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Dendritic Cell Therapy for Oncology – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
DNX-2401 – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
eflornithine hydrochloride – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ETS-2101 – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
galunisertib – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
mibefradil dihydrochloride – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
panobinostat – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
plerixafor – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
rindopepimut – Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Stem Cell Therapy for Glioma – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
vocimagene amiretrorepvec + flucytosine ER – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Oligodendroglioma – Recent Pipeline Updates 74
Oligodendroglioma – Dormant Projects 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 93
Disclaimer 94